๐จ๐ช๐ผ๐๐น๐ฑ ๐๐ผ๐ ๐ฒ๐ฑ๐ถ๐ ๐ฎ ๐ด๐ฒ๐ป๐ฒ ๐๐ผ ๐น๐ผ๐๐ฒ๐ฟ ๐๐ฟ๐ถ๐ด๐น๐๐ฐ๐ฒ๐ฟ๐ถ๐ฑ๐ฒ๐?
CTX310: one infusion targeting #ANGPTL3; mean triglycerides down 63% at 30 days in ten adults with severe hypertriglyceridemia.
The promise is lasting lipid control. The evidence is an uncontrolled phase 1b cohort.
Long-term safety and prevention of pancreatitis or cardiovascular events remain unproven.
These early findings deserve attention and larger, longer studies.
What evidence would you require before considering gene editing in routine lipid care?
@CRISPRTX @AHAScience
#CardioCircle #CardioX #CardioTwitter #Cardiology #medX #GeneEditing
๐จ๐ช๐ต๐ฒ๐ฟ๐ฒ ๐๐ฒ ๐ฝ๐ฎ๐ฐ๐ฒ ๐บ๐ฎ๐๐๐ฒ๐ฟ๐.
โก๏ธOptimPacing strengthens the case for protecting ventricular function from the first implant.
๐ข With left bundle branch versus right ventricular pacing, the composite of death, heart failure hospitalization, or pacing-induced cardiomyopathy occurred in 16/342 (4.7%) versus 35/343 (10.2%) over a median of 35 months.
๐ขThe hazard was 59% lower, but early stopping warrants caution. A composite benefit does not establish a survival benefit.
๐ฌReliable pacing is the starting point. How we deliver it deserves attention.
@AHAScience @NEJM
#CardioCircle #CardioX #CardioTwitter #EPeeps #ScientificSessions26 #CSP #RVP #LBBP #LBBAP
๐จ๐ง๐ต๐ฒ ๐๐ ๐ฑ๐ถ๐๐ถ๐ฑ๐ฒ๐ป๐ฑ ๐บ๐ฎ๐ ๐ฏ๐ฒ ๐๐ถ๐บ๐ฒ.
๐ขAt #ScientificSessions26, AI drafts cut cardiologistsโ echo interpretation time from 8.5 to 4.6 minutes.
๐ขSubstantial edits were needed in 50.6% of AI drafts versus 49.7% of human drafts. Cardiologists finalized every report.
๐ขThese are preliminary workflow findings; improved patient outcomes were not assessed.
โก๏ธThe next test: whether time saved reaches patients through faster reporting and better access.
@HeartNews
#CardioCircle #CardioX #Cardiology #CardioTwitter #MedTech #medicaldevices #Digitalhealth #AIinHealthcare
๐ด๐ฆ๐๐ผ๐ฝ ๐ผ๐ฟ ๐ฐ๐ผ๐ป๐๐ถ๐ป๐๐ฒ? ๐ ๐ฎ๐ธ๐ฒ ๐๐ต๐ฒ ๐ฐ๐ต๐ผ๐ถ๐ฐ๐ฒ ๐ถ๐ป๐ณ๐ผ๐ฟ๐บ๐ฒ๐ฑ.
SAGA/SITE and STREAM studied statin discontinuation in older adults without established cardiovascular disease.
Both met non-inferiority criteria, using different outcomes and follow-up. STREAM recorded more composite events after stopping.
Here are the absolute numbers, comparing ๐ฆ๐ง๐ข๐ฃ versus ๐๐ข๐ก๐ง๐๐ก๐จ๐:
๐ข๐ฆ๐๐๐/๐ฆ๐๐ง๐ โก๏ธ all-cause deaths at three years, among participants with available mortality data:
โข 35/484 (7.2%) versus 48/604 (7.9%).
๐ข๐ฆ๐ง๐ฅ๐๐๐ โก๏ธ nonfatal heart attack, nonfatal ischemic stroke or death:
โข First two years: 100/938 (10.7%) versus 77/942 (8.2%).
โข Full observed follow-up, extending up to four years: 119/938 (12.7%) versus 87/942 (9.2%).
These are different endpoints and time windows; the percentages should be compared within each trial.
Stopping reduces pill burden, but neither trial demonstrated better quality of life after discontinuation.
Patients should understand the possible loss of cardiovascular protection, alongside uncertainty about their individual benefit.
Discuss absolute risks, tolerability, life expectancy and what matters to them. Then decide together.
@AHAScience
#CardioCircle #CardioX #Cardiology #Statins #STREAM #AHA2026
๐จModerate stenosis does not always mean low stakes.
#PROGRESS challenges the timing of TAVR: among 744 patients with moderate aortic stenosis and at-risk features, earlier intervention โฌ๏ธreduced the combined endpoint of death or heart failure events at two years.
๐ขThe benefit came from fewer heart failure events; a survival advantage was not demonstrated.
Patient selection becomes the central issue.
How much weight should symptoms and cardiac damage carry before the valve becomes โsevereโโ
@NEJM @EdwardsLifesci @crfheart
nejm.org/doi/full/10.1056/NEโฆ
#CardioCircle #CardioX #CardioTwitter #TCT2026 #TAVR
Where should the stent landโ๏ธ In P4, planning started on coronary CT.
CT-guided PCI was noninferior to IVUS-guided PCI for 1-year target-vessel failure (4.1% vs 4.6%). Median PCI time was 46 vs 63 min.
@ColletCarlos @NEJM @crfheart #TCT2026 #CardioCircle #CardioX #CardioTwitter #CCTA
doi.org/10.1056/NEJMoa261077โฆ
CardioCircle retweeted
Important conversations on the role of:
1) @FDA EFS & FIH trials
2) #MedTech in improving access to innovations
๐กInnovation ๐Implementation
โIt takes an average of 17 years for medtech solutions to reach practiceโ #PeterFitzgerald
๐กCV care will exceed 1Trillion ๐ต by 2030
๐กGBD: Efficacy of vaccines 80-90% & current management of hypertension reaches only 25%
โก Day One starts with the science youโll be talking about.
Dive into Featured Clinical Research at #TCT2026 WorldLink Forum for new data, hot topics, and a special session in partnership with Structural Heart ow.ly/eE6S5102GO8
#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD @m1chaella_alex @CathWhisperer @caldera_99 @SinaDaneshMD @CAESmedmd @Julio_Farjat @GolzarianH @JyotiJain_MD @Shikha_Cardio @DrBilal_khan @KrutarthKPandya @Shoaib9702 @IoannisSkalidis @Sticchi_Alex @ricosuruagy @ladyheart_md @AnaClaraVi75147 @anast_apost @padideh_daneii @MAnisHaider @Rushil_Vasudev
๐จValve care cannot stop at a successful implant.
Closing a heart valve leak without another open-heart operation.
Paracloseโs value lies in what it may spare suitable patients: another open-heart operation.
@AbbottNews announced FDA approval for Paraclose, a catheter-delivered plug for leaks around surgical replacement valves.
How we manage the next intervention belongs in our definition of success.
#CardioCircle #CardioX #CardioTwitter #StructuralHeart #MedTech
๐ง๐๐ง ๐ฎ๐ฌ๐ฎ๐ฒ: ๐ญ๐ฎ ๐๐ฟ๐ถ๐ฎ๐น๐ ๐๐ผ ๐๐ฎ๐๐ฐ๐ต.
Coronary imaging, valve intervention, antithrombotic therapy, and renal denervation are all on our radar.
๐ San Diego | 31 Octoberโ3 November
From Cardiovascular Research Foundationโs program (@crfheart), hereโs CardioCircleโs watchlist:
๐ฆ๐จ๐ก๐๐๐ฌ โข ๐ญ ๐ก๐ข๐ฉ๐๐ ๐๐๐ฅ
๐น P4 โก๏ธ Coronary CT versus IVUS to guide PCI. @ColletCarlos
๐น TRANSFORM II โก๏ธ Sirolimus-coated balloons challenge everolimus-eluting stents. @BernardoCortese @conceptmedicals
๐น HD-PCI โก๏ธ Finding the right heparin dose during PCI.
๐น REMEDY-PILOT โก๏ธ A sham-controlled test of a coronary sinus reducer for refractory angina without obstructive coronary disease. @JNJMedTech @ShockwaveIVL
๐น TRAVEL III โก๏ธ LuX-Valve Plus replacement versus medical therapy for severe tricuspid regurgitation.
๐ ๐ข๐ก๐๐๐ฌ โข ๐ฎ ๐ก๐ข๐ฉ๐๐ ๐๐๐ฅ
๐น PROGRESS โก๏ธ Earlier TAVR for selected patients with moderate aortic stenosis. @PhilGenereuxMD
๐น CLASP II TR โก๏ธ What #PASCAL repair adds to medical therapy for severe, symptomatic tricuspid regurgitation. @EdwardsLifesci
๐น SIMPLAAFY โก๏ธ Simplifying antithrombotic treatment after left atrial appendage closure. @bostonsci
๐ง๐จ๐๐ฆ๐๐๐ฌ โข ๐ฏ ๐ก๐ข๐ฉ๐๐ ๐๐๐ฅ
๐น PIONEER IV โก๏ธ Using angiography-derived coronary physiology to guide PCI.
๐น EPIC17-VERONICA โก๏ธ Platelet testing to guide antiplatelet de-escalation after acute coronary syndromes.
๐น SPYRAL AFFIRM โก๏ธ US post-approval evidence for radiofrequency renal denervation. @Medtronic @Kandzari
๐น PROTEMBO IDE โก๏ธ Testing cerebral embolic protection during TAVR. #protembis
These upcoming presentations could inform patient selection, procedural choices, and the balance between benefit and harm.
Which trial is highest on your watchlist, @TCTMDโ๏ธ
@PCRonline @TCTConference @HeartFlow @Cleerly @ElucidBio @SiemensHealthES
#CardioCircle #TCT2026 #CardioX #InterventionalCardiology #StructuralHeart #TAVR #PCI #DrugCoatedBalloons #LAAO #RenalDenervation #ClinicalTrials #MedTech #Cardiology #P4 #CTguidedPCI #CCTA #ANOCA
CardioCircle retweeted
Free tools built by clinicians for learning the many facets of cardiology๐ซ๐ฉปโก๏ธ๐งฎ๐๐น๏ธ
Explore these resources๐๐ผ:
๐ฉปEchocardiography: intro2echo.com by @David_Ouyang
๐ฉปAngiography Views: angioview.com by @AnnasRahmanMD
โก๏ธLocalize PVCs: learnpvcs.com by @Challa1218
โก๏ธLocalize VTs: simvt.vercel.app by @ArunUMahtani
โก๏ธLBBAP Simulator: pacingsimulator.com by @jo3_assad
๐ฉปLAA TEE/ICE/CT Simulator: laa.liorjankelson.com by @ExtraStim
๐งฎInteractive Core Cardiology Tools and Calculators: tools.rueyhu.com by @ruey_hu
๐Latest Trials and Guidelines: cardiolads.com by Jay Gohri, Adhish Beri, and @KochharGunjan
๐ฉปInteractive M Mode: pulmonarypocus.com by @HoosierPocus
๐น๏ธNight Float Simulator: cardsnightfloat.netlify.app by @AbedfromBeirut
๐น๏ธCongenital Heart Disease, Pacemaker, ECG Simulators: cardiorender.com by Dinesh Raja P
This list keeps growing. Know a free, clinician-built tool that belongs here? Drop the link below
#Cardiology #CardioTwitter #MedEd #MedTwitter #FOAMed #VibeCoding #AI #AIinMedicine #LLMs #DigitalHealth
@ACCinTouch @escardio @ASE360 @Heart_SCCT @HRSonline @SCAI @CardioNerds
๐ง๐ต๐ฒ ๐๐๐ฒ๐๐ต๐ผ๐๐ฐ๐ผ๐ฝ๐ฒ ๐ด๐ฒ๐๐ ๐ฎ๐ป ๐๐ ๐๐ฝ๐ด๐ฟ๐ฎ๐ฑ๐ฒ.
@Eko_Healthโs #FDA-cleared CORE 300 combines analog listening with up to 35ร digital amplification, noise cancellation, and a heart-rate display.
Connect it to the Eko App with Eko+ membership for AI-supported structural murmur detection.
Our take: fitting AI into a familiar bedside tool could make adoption easier. Its clinical value will depend on how those findings guide further evaluation and care.
Would you add AI to your stethoscopeโ๏ธ
#CardioCircle #CardioX #CardioTwitter #MedTech #medicaldevices #Digitalhealth #AIinHealthcare
๐ง๐๐ผ ๐น๐ฒ๐ฎ๐ฑ๐. ๐๐๐ฟ๐ถ๐ฎ๐น ๐๐ฒ๐ป๐๐ถ๐ป๐ด. ๐ฅ๐ฒ๐๐๐ป๐ฐ๐ต๐ฟ๐ผ๐ป๐ถ๐๐ฎ๐๐ถ๐ผ๐ป.
#BIOTRONIK announced the first US Acticor Sky CRT-DX implant, performed by Dr. Niraj Varma at @ClevelandClinic.
DX technology enables atrial sensing within a two-lead CRT-D system. The platform also includes HeartInsight alerts for worsening heart failure.
The practical attraction: less implanted hardware while retaining atrial information in appropriately selected patients.
A first implant marks adoption; comparative clinical value requires evidence.
Which patients would you consider the best candidates for this approach in your practiceโ๏ธ
@BIOTRONIK_News
#CardioCircle #CardioX #CardioTwitter #EPeeps #HeartFailure #MedTech
๐ ๐ป๐ฎ๐๐ฎ๐น ๐๐ฝ๐ฟ๐ฎ๐ ๐ณ๐ผ๐ฟ ๐๐ ๐ฟ๐ฎ๐๐ฒ ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐น?
๐จMilestoneโs ReVeRA-301 Phase 3 trial has expanded into Europe.
It tests self-administered #etripamil for symptomatic AF with rapid ventricular rate, measuring rate reduction within 30 minutes and symptom improvement.
CARDAMYST is #FDA-approved for acute symptomatic PSVT in adults. AF use remains investigational.
๐ขThe question is compelling: could selected patients eventually manage these episodes outside hospital under a prescribed treatment planโ๏ธ
Phase 3 results must establish the benefit and safety of this approach.
@MIST_Milestone
#CardioCircle #CardioTwitter #CardioX #medX #AFib
๐จ๐ฅ๐ฒ๐ฝ๐ฎ๐ถ๐ฟ ๐๐ต๐ฒ ๐น๐ฒ๐ฎ๐ธ. ๐๐บ๐ฝ๐ฟ๐ผ๐๐ฒ ๐ผ๐๐๐ฐ๐ผ๐บ๐ฒ๐.
In TRIC-I-HF, transcatheter tricuspid repair added to medical therapy lowered the hazard of death or heart-failure hospitalization in selected high-risk patients with severe tricuspid regurgitation.
HR: 0.40 through three years.
#PASCAL and #TriClip were the main repair systems used.
The trial evaluated an intervention strategy, not which device is superior.
For structural-heart teams and industry, the focus now includes patient selection, referral pathways, and delivery of treatment.
How should this evidence change your heart-team discussionโ๏ธ
#CardioCircle #CardioX #CardioTwitter #MedTech #StructuralHeart
๐จ๐ช๐ต๐ถ๐ฐ๐ต ๐ป๐ฎ๐ฟ๐ฟ๐ผ๐๐ถ๐ป๐ด ๐ป๐ฒ๐ฒ๐ฑ๐ ๐ฎ ๐๐๐ฒ๐ป๐?
AIR-STEMI used angiography-derived physiology to guide non-culprit PCI after successful culprit treatment in STEMI.
๐ขThe primary composite- death, MI, stroke, or ischemia-driven revascularization- was lower: 8.9% vs 13.7%.
๐ขFewer non-culprit vessels received PCI.
๐ดMortality alone was not significantly reduced.
The technology story: software can turn angiographic images into information that changes treatment decisions.
The implementation question: can cath labs reproduce this core-lab-supported strategy in everyday practiceโ๏ธ
#CardioCircle #CardioTwitter #CardioX #InterventionalCardiology #MedTech
๐จ๐๐ผ๐๐ฟ ๐บ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ๐. ๐ข๐ป๐ฒ ๐ฐ๐ฎ๐ฝ๐๐๐น๐ฒ.
A heart-failure polypill combines #bisoprolol, #losartan, #eplerenone, and #dapagliflozin.
In a 40-patient randomized pilot, pill-count adherence at four weeks was better than with usual care: 85% versus 47% took at least 80% of their doses.
Promising for simplifying treatment, but this small, short study does not establish fewer hospitalizations or deaths.
Could reducing pill burden help more patients stay on foundational heart-failure therapy?
The next challenge: preserving flexibility to adjust each medicine while making treatment easier to follow.
#CardioCircle #CardioTwitter #CardioX #medX #HeartFailure






















